Sequence background
BPC-157 is a 15-amino-acid synthetic fragment derived from a sequence first characterised in gastric-juice research literature. TB-500 is a synthetic 17-amino-acid fragment corresponding to the actin-binding region of thymosin β-4.
Proposed mechanisms
BPC-157 is most often discussed in the angiogenesis literature — VEGFR2 signalling, nitric-oxide pathway modulation and growth-factor expression in connective-tissue research models. TB-500 is studied for actin sequestration: its central KLKKTET motif binds G-actin and is associated with cell migration and remodelling in research literature.
Why they are often paired in research
The two compounds act on different layers of tissue-remodelling research models — BPC-157 on vascular and growth-factor signalling, TB-500 on the cytoskeletal actin pool. Researchers comparing the two typically note complementary rather than overlapping pathway coverage.
Handling and storage
Both peptides ship lyophilised and are stored at 2–8°C before reconstitution. Bacteriostatic water is the standard reconstitution solvent; refrigerated in-use storage applies to both. TB-500's larger fragment size does not change standard handling practice.
Batch documentation
Every Regena batch of BPC-157 and TB-500 ships with HPLC purity and mass-spec identity documentation, available on the lab reports page. Lot numbers on the vial label match the COA.
Choosing for a research protocol
Selection depends on the pathway the protocol targets. Angiogenesis and growth-factor endpoints typically reference BPC-157; actin-dynamics and migration endpoints typically reference TB-500. Always cross-check current literature before designing an in-vitro study.
Frequently asked questions
Are BPC-157 and TB-500 the same thing?+
No. They are distinct synthetic peptides with different sequences, different molecular weights and different proposed signalling pathways.
Is one more 'pure' than the other?+
Purity depends on the batch, not the molecule. Both are verified by HPLC; modern research-grade material is typically reported at 99%+.
Can the two be researched together in vitro?+
Researchers often pair them precisely because the pathways differ. Any combined-use research must follow the protocol's own controls and current literature.
Where can I see the COA?+
Lot-matched COAs for BPC-157 and TB-500 are published on the lab reports page.